An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

• Status: Terminated
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: PDL BioPharma, Inc.
• Treatments: Visilizumab

Criteria

Inclusion Criteria:

• Previous participation in a visilizumab study of IVSR-UC.

• Disease progression while enrolled in a previous visilizumab study, and subsequent treatment with salvage therapy.

Exclusion Criteria:

• Unable to understand the purpose and risks of the study, or unwilling or unable to provide a signed and dated informed consent.

• For U.S. sites, unwilling or unable to provide authorization to use protected health information.